Naratuximab emtansine

N/A

Report date: 2024/02/05 14:02:39

Base Information

Drug NameNaratuximab emtansine

Drug Alias NameIMGN-529K7153A-SMCC-DM1

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > SMCC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM1 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionTubulin polymerisation inhibitorsLeukocyte antigen CD37 antagonists

TargetsLeukocyte antigen CD37Tubulin

Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-CellLymphoma, Non-Hodgkin +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaBelgiumBulgaria +[9]

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesImmunogen Inc

China Registration ClassN/A

Develop Information

Active CompaniesDebiopharm International Sa

Inactive CompaniesImmunogen Inc

Active IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell

Inactive IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A